Rich countries must donate a billion vaccines by September or risk new COVID-19 variants12th May 2021
As nearly 160 million COVID-19 cases have been detected across the world, new variants of the virus have emerged.
Recent clinical trials have found the Pfizer vaccine is about 70 per cent effective in preventing symptomatic cases of the B1.351 variant, also known as the South African variant, although close to 97 per cent effective at preventing serious disease and death.
While larger trial results for the AstraZeneca vaccine are still to be seen, an early, smaller trial found it offered little protection against this variant.
The WHO warned new variants will continue to develop for as long as the virus circulates. In India, where daily cases have reached more than 400,000, the more recent B1.617 variant has become widespread.
“The more the virus spreads, the more likely there will be newer variants,” said Professor Mike Toole, an epidemiologist at the Burnet Institute.
“The virus mutates randomly, and it mutates more slowly than a lot of other viruses: about twice a month.
“Most of those mutations die out, but some of them don’t and are a problem.”
Other immediate recommendations made by the WHO in the report, titled Make It the Last Pandemic, included measures to make vaccines easier to produce in poorer nations.
It recommended the World Trade Organisation and the WHO convene vaccine-producing countries and manufacturers to determine voluntary licensing and technology transfer agreements for the vaccines.
If this does not occur within three months, it called for an immediate waiver of intellectual property rights over the vaccines.
US President Joe Biden has voiced support for waiving intellectual property protections for COVID-19 vaccines, a push which has been led at the WTO by India and South Africa, although faced European opposition.
Professor Toole said he believed licensing agreements, such as the arrangement between Melbourne-based CSL and AstraZeneca and Novavax’s deal with the Serum Institute of India, were more useful than patent waivers.
“These mRNA vaccines are very complicated to manufacture and the patent doesn’t necessarily contain detailed instructions,” he said, adding that companies such as Pfizer and Moderna should consider the “very good” manufacturing facilities in Thailand and Indonesia for partnerships.
The WHO also called for G7 and G20 nations to provide $19 billion in funding for its Access to COVID-19 Tools Accelerator (ACT-A) partnership to strengthen global health systems.
Australia cut its foreign aid budget in Tuesday’s federal budget by $144 million to $4.335 billion for 2021-22, including $355 million to be spent on rolling out vaccines in the Pacific and South-East Asia.